- Home
- EE vs KALV Comparison
EE vs KALV Comparison
Compare EE & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- KALV
- Stock Information
- Founded
- EE 2003
- KALV N/A
- Country
- EE United States
- KALV United States
- Employees
- EE N/A
- KALV N/A
- Industry
- EE Oil/Gas Transmission
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- EE Utilities
- KALV Health Care
- Exchange
- EE Nasdaq
- KALV Nasdaq
- Market Cap
- EE 805.1M
- KALV 651.3M
- IPO Year
- EE 2022
- KALV N/A
- Fundamental
- Price
- EE $29.20
- KALV $11.34
- Analyst Decision
- EE Hold
- KALV Strong Buy
- Analyst Count
- EE 6
- KALV 8
- Target Price
- EE $31.17
- KALV $24.83
- AVG Volume (30 Days)
- EE 395.2K
- KALV 492.6K
- Earning Date
- EE 05-07-2025
- KALV 07-10-2025
- Dividend Yield
- EE 0.82%
- KALV N/A
- EPS Growth
- EE 37.63
- KALV N/A
- EPS
- EE 1.53
- KALV N/A
- Revenue
- EE $966,414,000.00
- KALV N/A
- Revenue This Year
- EE $13.96
- KALV N/A
- Revenue Next Year
- EE $39.55
- KALV N/A
- P/E Ratio
- EE $19.20
- KALV N/A
- Revenue Growth
- EE N/A
- KALV N/A
- 52 Week Low
- EE $16.70
- KALV $7.30
- 52 Week High
- EE $32.99
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- EE 62.90
- KALV 39.50
- Support Level
- EE $24.76
- KALV $11.31
- Resistance Level
- EE $30.10
- KALV $12.71
- Average True Range (ATR)
- EE 0.90
- KALV 0.68
- MACD
- EE 0.51
- KALV -0.22
- Stochastic Oscillator
- EE 84.83
- KALV 4.66
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.